Kornimate/medical-research-clean huggingface dataset:
lung ultrasound in pleuritic chest pain

Conditions: Community Acquired Pneumonia; Pleuritis; Pulmonary Embolism; Lung Cancer

Summary: chest pain is an alarming symptom and one of the most frequent causes of access to the emergency departement. although chest x-ray remains an essential step in the diagnostic process, several studies showed numerous limitations of radiography which frequently is inconclusive. ultrasonography is a non-radiating imaging technique. albeit a wide use of ultrasound, the utilization of ultrasound in the study of the lung has only recently been introduced in the clinical practice. several studies proved that lung ultrasound is useful in the diagnosis of lung consolidation in community acquired pneumonia. nowadays, ultrasound is not routinely used in the presence of chest pain. our hypothesis based on clinical experience is that, in patients with pleuritic chest pain, lung ultrasound is very sensitive in detecting pneumonia and other lung diseases (such as pneumothorax) thus performing better than radiography. the primary aim of this study is to verify, in patients affected by pleuritic chest pain, the accuracy of lung ultrasound compared to chest-x-ray. the secondary aim is to evaluate the accuracy of lung ultrasound consolidations in distinguishing lung consolidation in pneumonia, atelectasis, pulmonary infarction, or tumors.


Eligibility criteria:
inclusion criteria: * patient aged 18 years and older * patient affected by thoracic pleuritic pain exclusion criteria: * patient affected by a chronic condition causing thoracic pain * patient affected by acute cardiovascular diseases (e.g. acute coronary syndrome)

Keywords: lung ultrasound community acquired p neumonia (cap) pleuritis pulmonary embolism lung cancer
an efficacy and safety study of xp19986 in subjects with symptomatic gerd

Conditions: Gastroesophageal Reflux

Summary: to evaluate efficacy and safety of treatment with xp19986 sustained release (sr) tablet compared to placebo in subjects with symptomatic gerd


Eligibility criteria:
inclusion criteria: * history and documentation of gerd diagnosed by a gastroenterologist, with symptoms (heartburn and/or regurgitation) on ≥ 3 days during the week prior to screening and prior to randomization exclusion criteria: * current or historical endoscopic evidence of erosive esophagitis la classification grade b, c, or d
to evaluate the efficacy and safety of balloon catheter combined with oxytocin induction in nulliparous women with estimated fetal weight ≥3500g at 39-40 weeks of gestation

Conditions: Macrosomia, Fetal

Summary: this study is a randomized, controlled, observational study. 150 nulliparous women with estimated fetal weight ≥3500g at 39-40 weeks of gestation will be enrolled as subjects in the two groups is 1:1. in the experimental group, vaginal examination will be performed at 39 to 40 weeks to assess cervical conditions. if the bishop score \<6, the balloon catheter combined with oxytocin induction will be planned at 40 weeks ±3 days. in the control group, one week to 41 weeks ±3 days will be expected. vaginal examination will be performed again to evaluate cervical conditions. if the bishop score \<6 points, and balloon catheter combined with oxytocin induction will be performed. after 96h, their final delivery mode will be recorded. in the following 42 days postpartum, their complications and the neonatal outcome will be followed up.


Eligibility criteria:
inclusion criteria: singleton head position pregnancy, negative down's screening and /or nipt screening, no malformation was found, with slight/without pregnancy complications - exclusion criteria:twin or multiple pregnancy, scar uterus, with contraindications to vaginal delivery, estimated fetal weight \>4500g -

Keywords: balloon catheter oxytocin
plasmakinetic enucleation of the prostate to treat benign prostatic hypertrophy patients with large prostate

Conditions: BPH With Large Prostate

Summary: the goal of this study is to compare the perioperative and postoperative characters of plasmakinetic enucleation of the prostate(pkep) with bipolar turp(b-turp) for bph patients with large prostate.

despite the availability of numerous minimally invasive alternatives, monopolar transurethral resection of the prostate (turp) remains the most frequently performed operation for benign prostatic hypertrophy (bph) with small to moderate size prostates. nevertheless, turp for large prostates is associated with various complications and unsatisfactory long-term results. b-turp and pkep have both been proved to have more favorable postoperative outcomes than monopolar turp. but whether b-turp or pkep is better remain controversial. we aim to compare the perioperative and postoperative characters of pkep with b-turp for bph patients with large prostate. moreover, we evaluate the long-term results of both approaches.

Eligibility criteria:
inclusion criteria: * qmax \ 19 * age between 50 and 70 years * prostate volume between 70 and 200 ml, as determined by trus, and medical therapy failure. exclusion criteria: * patients with neurogenic bladder * urethral stricture * bladder tumor * prostate cancer and previous prostate bladder neck * urethral surgery * psa\>4ng/ml, or receiving prostate biopsy within 3 months

Keywords: benign prostatic hypertrophy bipolar transurethral resection of the prostate plasmakinetic enucleation of the prostate
effect of gabab agonist on visceral hyperalgesia in nccp patientschinese?

Conditions: Non-Cardiac Chest Pain

Summary: the effect of baclofen (gabab agonist), diltiazem (muscle relaxant) and placebo will be compared in a double-blinded randomized study for the treatment of nccp. cerebral cortical, brainstem and spinal evoked potentials before and after treatment will be evaluated. results of this study will shed lights on pathogenesis and treatment of nccp in chinese.we hypothesize that baclofen alleviates visceral hyperalgesia in nccp patients by suppressing afferent sensory pathway.


Eligibility criteria:
inclusion criteria: * consecutive patients with monthly angina-like chest pain and negative coronary angiogram or scintigraphy * age between 18-70 * gastroesophageal reflux disease * psychiatric illness * cerebrovascular accident * active peptic ulceration * heart failure or cardiac bradyarrhythmia * epilepsy * pregnancy or lactating female * previous hypersensitivity to muscle relaxant
pregabalin and analgesia after laparoscopic cholecystectomy

Conditions: Pain Postoperative

Summary: the purpose of this study is to evaluate how effective is the preoperative administration of pregabalin 600mg, to attenuate postoperative pain and opioids consumption after laparoscopic cholecystectomy.

acute pain frequently occurs during the postoperative period.not treated acute postoperative pain may predict the development of chronic pain.recently, the analgesic effect of pregabalin, as a part of a multimodal analgesia, has been evaluated in many studies. they have shown that pregabalin may have a role in the post operative pain management, as an adjunct. pregabalin is an anticonvulsant and anxiolytic drug, which have a more favorable pharmacokinetic profile from its predecessor gabapentin. acute postoperative pain after laparoscopic cholecystectomy is complex in nature. postoperative pain is the main complaint and the primary reason for delay discharge after laparoscopic cholecystectomy.the study includes patients undergoing laparoscopic cholecystectomy.

Eligibility criteria:
inclusion criteria: * asa physical status i-ii exclusion criteria: * renal or hepatic insufficiency * alcohol or drugs abuse * history of chronic pain or daily intake of analgesics * uncontrolled medical disease (hypertension, diabetes) and cardiovascular problems. psychiatric disorders * inability of patients to use pca pump * history of intake of non-steroidal anti-inflammatory drugs the last 24 hours before surgery,use of drainage after the surgery

Keywords: pregabalin laparoscopic cholecystectomy postoperative pain opioid consumption
novel epothilone plus capecitabine versus capecitabine alone in patients with advanced breast cancer

Conditions: Breast Cancer; Metastases

Summary: the purpose of this clinical research study is to learn if bms-247550 added to the approved therapy of capecitabine is better than capecitabine alone in shrinking or slowing the growth of the cancer in women with metastatic breast cancer who are resistant to taxane and received anthracycline chemotherapy. the safety of this treatment will also be studied.


Eligibility criteria:
* patients must have received either 2 or 3 prior chemotherapy regimens including adjuvant or neoadjuvant therapy. * prior treatment must have included both an anthracycline (i.e., doxorubicin or epirubicin) and a taxane (i.e., paclitaxel or docetaxel). * patients must have received a minimum cumulative dose of anthracycline or must be resistant to an anthracycline. * patients must be resistant to taxane therapy. * patients may not have any history of brain and/or leptomeningeal metastases. * patients may not have ctc grade 2 or greater neuropathy (motor or sensory). * patients may have not have had prior treatment with an epothilone and/or capecitabine (i.e., xeloda)

Keywords: metastatic breast cancer
delgocitinib cream for the treatment of moderate to severe atopic dermatitis during 8 weeks in adults, adolescents, and children

Conditions: Atopic Dermatitis

Summary: this is a multi-center, open-label trial to evaluate safety and pharmacokinetics of topical delgocitinib cream applied to pediatric subjects (2-17 years) and adult subjects (18 years and above) with atopic dermatitis.

a phase 1 open-label, multi-centre, single-arm trial to evaluate the safety and pharmacokinetics (including must) of twice daily topical application of delgocitinib cream for 8 weeks in adults, adolescents, and children with moderate to severe atopic dermatitis

Eligibility criteria:
key inclusion criteria (part 1: adults and adolescents; 12 years and above) * diagnosis of atopic dermatitis (ad) as defined by the hanifin and rajka (1980) criteria for ad * age 12 years and above at baseline * ad involvement of 25-50% treatable body surface area (bsa) at screening and at baseline * moderate to severe ad (validated investigator global assessment scale for atopic dermatitis \[viga-ad\] score of at least 3) at screening and at baseline key inclusion criteria (part 2: children; 2-11 years) * diagnosis of ad as defined by the hanifin and rajka (1980) criteria for ad * age 2-11 years at baseline * history of ad for at least 3 months (children aged 2-5 years), and at least 12 months (children aged 6-11 years) * ad involvement of ≥35% treatable bsa at screening and at baseline * moderate to severe ad (viga-ad score of at least 3) at screening and at baseline key exclusion criteria (part 1 and 2: subjects aged 2 years and above) * active dermatologic conditions that may interfere with the diagnosis of ad * use of tanning beds or phototherapy within 4 weeks prior to baseline * systemic treatment with immunosuppressive/modulating drugs or corticosteroids within 4 weeks prior to baseline or 3 or more bleach baths any week within 4 weeks prior to baseline * treatment with topical corticosteroids (tcs), topical calcineurin inhibitors (tcis), topical phosphodiesterase-4, or oral antibiotics within 1 week prior to baseline * clinically significant infection (systemic infection or serious skin infection requiring parenteral treatment) within 4 weeks prior to baseline * any disorder, which is not stable, and in the investigator's opinion could affect the safety of the subject, influence the results of the trial or impede the subject's ability to complete the trial

Keywords: adults, pediatric
airwaze - easy and advanced tools for cbct guided lung interventions

Conditions: Lung Diseases

Summary: the goal of this clinical trial is to assess the overall usability of the philips airwaze investigational device in patients indicated for cbct-guided navigation bronchoscopy procedure. the main questions it aims to answer are to assess the: * overall usability of the device * accuracy of the tool-in-lesion confirmation scan participants will undergo bronchoscopy with the new navigation device and additional confirmation scans. follow-up visit at 7days will be performed.


Eligibility criteria:
inclusion criteria: * age 18 years or older at the time of informed consent. * asa physical status between 1 and 3. * subject is willing and able to give written informed consent for clinical investigation participation prior to the procedure. * subject has a pulmonary lesion with an indication for diagnostic evaluation following current clinical guidelines and/or as decided by multi-disciplinary team consultation. * suitable for cbct-guided endobronchial nodule biopsy under general anaesthesia. * pre-procedural (pet-)ct scan is available prior to the cbct-nb intervention. exclusion criteria: * aged 17 or younger at the time of informed consent. * asa physical status is equal to and greater than 4. * not willing or not able to give informed consent. * does not indicate diagnostic evaluation with navigation bronchoscopy. * not suitable for cbct-guided endobronchial nodule biopsy via navigation bronchoscopy under general anaesthesia. * there is no recent pre-procedural (pet-)ct scan available. * known bleeding disorders. * contra-indication for temporary interruption of the use of anticoagulant therapy, such as acenocoumarol, warfarin, therapeutic dose of low molecular weight heparins, clopidogrel, or analogues, noacs). * known allergy for lidocaine or other allergies interfering with the procedure. * uncontrolled pulmonary hypertension. * recent and/or uncontrolled cardiac disease. * compromised upper airway (e.g. concomitant head and neck cancer or central airway stenosis for any reason such that endobronchial access is considered unsafe). * potentially confounding drug or device trial during the clinical study. co-enrollment in concurrent trials may be allowed provided pre-approval is obtained from the philips clinical study manager. * all vulnerable subjects, such as immune-compromised subjects, subjects lacking the capacity to provide consent, patients in emergencies, pregnant or breastfeeding women, or any other subject who meets exclusion criteria, according to applicable national laws, if any. * woman of childbearing potential who is known to be pregnant on admission. * any condition that in the judgment of the investigator could impose hazards to the patient if study therapy is initiated or affect the participation of the subject in the study. * subject is philips employee or their family members residing with this philips employee.
coronary ct angio evaluating graft patency in acs patients treated with dapt or single asa after cabg (cocap)

Conditions: Acute Coronary Syndrome; Coronary Bypass Stenosis

Summary: the purpose of this study is to compare the presence of graft patency in single aspirin vs dual anti platelet therapy (dapt) treatment including ticagrelor in patients with acute coronary syndrome (acs) treated with coronary artery bypass surgery (cabg). follow up time is 12-36 months postoperatively and the patency will be evaluated with coronary computed tomography angiography (ccta)


Eligibility criteria:
inclusion criteria: * previously included in tacsi-trial exclusion criteria: * highly irregular heart rhythm (i.e. atrial fibrillation) * chronic kidney disease with estimated glomerular filtration rate (egfr) \<45ml/min/1,73m2 * body weight \>120 kg * previous severe allergic reaction (i.e. anaphylactic reaction) to iodine-based contrast agents * not able to communicate * not willing to participate

Keywords: acute coronary syndrome coronary bypass surgery coronary computed tomography angiography antiplatelet therapy
evaluation of the progression of disease and health-related quality of life in patients with pulmonary hypertension: a local clinic-based registry

Conditions: Pulmonary Hypertension

Summary: pulmonary hypertension (ph) is a multifaceted disease and is associated with significant morbidity and mortality if untreated1. diagnosing ph can be challenging and often delayed2. multiple international registries included reveal3 and compera4 have all demonstrated that diagnostic delay and suboptimal treatment prescription led poor 1 year-survival in patient with ph. in recent years, significant progress has been made in diagnosing, risk stratification, and treatment for patients with ph1. a dedicated ph service has been established in ambulatory clinic to streamline the management of these complex patients. this registry therefore aims to investigate the progression disease and its impact on the quality of life (qol) of the patients who are managed at the dedicated ph clinic.

pulmonary hypertension (ph) is a multifaceted disease and is associated with significant morbidity and mortality if untreated1. diagnosing ph can be challenging and often delayed2. multiple international registries included reveal3 and compera4 have all demonstrated that diagnostic delay and suboptimal treatment prescription led poor 1 year-survival in patient with ph. in recent years, significant progress has been made in diagnosing, risk stratification, and treatment for patients with ph1. a dedicated ph service has been established in ambulatory clinic to streamline the management of these complex patients. this registry therefore aims to investigate the progression disease and its impact on the quality of life (qol) of the patients who are managed at the dedicated ph clinic.

Eligibility criteria:
inclusion criteria: * patients age \> 18 with echocardiographic confirmation of increased pulmonary pressure (eg. estimated rvsp \>40mmhg, evidence of rv dilatation etc), and no apparent reversible causes. * patients with reasonable pre-morbids and is able to attend ambulatory clinic. exclusion criteria: * inability to provide valid consent by the patient or his legal guardian

Keywords: pulmonary hypertension six-minute walking test nt-probnp
galantamine effects on cognitive function in abstinent cocaine users

Conditions: Cocaine Abuse

Summary: to evaluate galantamine's effects on cognitive performance in abstinent cocaine users. galantamine, a medication approved for treatment of alzheimer's disease, is an acetylcholine esterase inhibitor. galantamine also directly potentiates nicotine receptors. both of these effects may result in improved cognitive performance in a group of subjects known to have impaired performance in various cognitive tasks.

galantamine, compared to placebo, will improve cognitive performance in abstinent cocaine users. the cognitive performance will be measured with the stroop test and 3 cambridge neuropsychological test automated battery (cantab) tests: paired associate learning (pal), delayed pattern recognition memory (prm),and rapid visual information processing (rvip). performance on these tests has been shown to be impaired in abstinent cocaine users, compared to healthy controls. galantamine, compared to placebo, will not be associated with any significant changes in mood. monitoring of mood will be achieved with 3 mood scales: 1) center for epidemiologic studies depression (ces-d) scale, positive and negative affect schedule (panas) and the profile of mood states (poms). currently this study is completed, patients are no longer being enrolled. there were 28 completers. this study has been published.

Eligibility criteria:
inclusion criteria: * male and females, between the ages 21 and 50 * fulfill criteria for past cocaine dependence * no cocaine use for the past 30 days * no other current dependence or abuse of other drugs or alcohol * no current medical problems and normal ecg * not pregnant,nor breast feeding, * using acceptable birth control methods. exclusion criteria: * current major psychiatric illness including mood, psychotic or anxiety disorders * history of major medical illnesses; including asthma or chronic obstructive lung disease, history or current gastrointestinal ulcer, hepatic or renal impairment and cardiac rhythm disturbances * use of other medications including,drugs that slow heart rate * known allergy to galantamine

Keywords: cognitive enhancers nootropic agents
pegylated liposomal doxorubicine and prolonged temozolomide in addition to radiotherapy in newly diagnosed glioblastoma

Conditions: Glioblastoma

Summary: glioblastomas represent 40% of all tumors of the central nervous system (cns) and are among the most lethal tumors. temozolomide (tmz) combined with radiotherapy was the first substance to significantly improve the overall survival (to 14.6 months) as compared to surgery and radiotherapy alone and increased the proportion of patients surviving more than 2 years to 26%. tmz showed the best efficacy in patients with a methylated o6-methylguanine-dna methyltransferase (mgmt) promoter in part by eliminating stem cell-like tumor cells. among patients with a methylated mgmt promoter, the median survival after treatment with combined radio-chemotherapy was 21.7 months, as compared to 15.3 months among those who were assigned to radiotherapy only. in the absence of methylation of the mgmt promoter, there was a smaller and statistically insignificant difference in survival between the treatment groups. doxorubicin is one of the most effective substances in vitro against cells derived from glioblastoma. however, it has no significant effect in vivo due to poor blood-brain-barrier penetration. in a tumor model, tissue and csf-concentrations of doxorubicin were substantially increased when sterically stabilized liposomes were used resulting in a comparable clinical response using approximately half of the dose of stabilized liposomes compared to conventional doxorubicin. a pegylated formulation (peg-liposomal doxorubicin) even further improved the penetration of the blood-brain barrier. case series and two phase ii-studies in patients with recurrent glioblastoma have shown modestly promising results for peg-dox. in this study, the investigators treated patients with recurrent glioblastoma with 20 mg/m2 peg-dox on days 1 and 15 of each 28-day cycle. to determine the dose limiting toxicity of peg-dox combined with prolonged administration of tmz, the investigators performed a phase i part ahead of the phase ii study. to investigate, by means of a historical control analysis, if the addition of peg-dox to tmz and radiotherapy improves the survival of patients, the investigators chose similar inclusion criteria and identical tmz and radiotherapeutic regimes as in the eortc26981/ncic-ce.3 study.


Eligibility criteria:
inclusion criteria: * newly diagnosed glioblastoma * centrally confirmed histology * karnofsky performance score (kps) \> 70% * stable corticosteroids within 2 weeks before inclusion * leucocytes \> 3/ul, thrombocytes \> 100/ul, hb \> 10 g/dl * additional standard criteria exclusion criteria: * other tumor in history * pretreatment with radiotherapy to the brain

Keywords: glioblastoma first-line clinical trial peg-liposomal doxorubicin temozolomide radiotherapy phase 1 phase 2